Skip to main content
EU Science Hub
Patent

Radioimmunoconjugates for targeted alpha therapy

A radioimmunoconjugate for targeted alpha therapy comprises an alpha-emitter (e.g. Bi-213) linked to the monoclonal antibody C595. This radioimmunoconjugate is widely applicable in cancer therapy and is particularly efficient for treatment of...

Details

Identification
2722
Publication date
30 May 2016

Description

The present radioimmunoconjugate combines an alpha-emitting radioisotope (e.g. Tb-149, At-211, Bi-212, Bi-213 or Ac-225) with a monoclonal antibody against the MUC-1 receptor. A merit of the present invention is to have found a specific combination of radionuclide and antibody for RIT, which allows the killing of individual cancer cells with a very high efficacy and thus results in improved therapeutic effect.

The treatment using the present radioimmunoconjugates permits to overcome many deficiencies of prior art methods. Specifically, radiocolloid therapy is not suitable for adjunctive therapy as it is not selective of cancer cells. Beta and gamma emitting radionuclides have been coupled to specific monoclonal antibodies against cancer cells.

the production of the present radioimmunoconjugates can be carried out using conventional materials. The production and purification procedures for the preferred isotopes are well known. The preferred chelating agents are commercially available.

THE MAIN APPLICATION AREAS

  • radioimmunoconjugates for targeted alpha-immunotherapy

THE MAIN INNOVATIVE ASPECTS AND ADVANTAGES

  • radioimmunoconjugate that can be used in several cancer types with high therapeutical efficacy
Patent 2722.jpg
© European Union

Files

Radioimmunoconjugates for targeted alpha therapy
English
(HTML)
Download